BACKGROUND:Chromium picolinate (CP) has been reported to benefit patients with symptoms of atypical depression. METHODS: A placebo-controlled, double-blind, pilot study of CP was conducted in 15 patients with DSM-IV major depressive disorder, atypical type. Patients received 600 micro g of CP or matching placebo (PBO) for 8 weeks. RESULTS: Seven (70%) CP and zero (0%) PBO patients met responder criteria (p =.02). Other outcomes were consistent with greater effect of CP. Three patients on CP failed to show any improvement. Chromium picolinate was well tolerated. CONCLUSIONS:Chromium picolinate shows promising antidepressant effects in atypical depression. Its mechanism of action may relate to 5HT2A downregulation, increased insulin sensitivity, or to other effects.
RCT Entities:
BACKGROUND:Chromium picolinate (CP) has been reported to benefit patients with symptoms of atypical depression. METHODS: A placebo-controlled, double-blind, pilot study of CP was conducted in 15 patients with DSM-IV major depressive disorder, atypical type. Patients received 600 micro g of CP or matching placebo (PBO) for 8 weeks. RESULTS: Seven (70%) CP and zero (0%) PBO patients met responder criteria (p =.02). Other outcomes were consistent with greater effect of CP. Three patients on CP failed to show any improvement. Chromium picolinate was well tolerated. CONCLUSIONS:Chromium picolinate shows promising antidepressant effects in atypical depression. Its mechanism of action may relate to 5HT2A downregulation, increased insulin sensitivity, or to other effects.
Authors: Kimberly A Brownley; Ann Von Holle; Robert M Hamer; Maria La Via; Cynthia M Bulik Journal: J Psychosom Res Date: 2013-04-22 Impact factor: 3.006
Authors: L Brundin; C M Sellgren; C K Lim; J Grit; E Pålsson; M Landén; M Samuelsson; K Lundgren; P Brundin; D Fuchs; T T Postolache; L Traskman-Bendz; G J Guillemin; S Erhardt Journal: Transl Psychiatry Date: 2016-08-02 Impact factor: 6.222